Serotonergic antiseizure agent
Fenfluramine
Brand names: Fintepla
Adult dose
Dose: Initial 0.1mg/kg BD, titrate weekly to max 0.7mg/kg/day (without stiripentol) or 0.4mg/kg/day (with stiripentol). Total max 26mg/day
Route: PO
Frequency: BD
Paediatric dose
Dose: 0.1 mg/kg
Route: PO
Frequency: BD
Max: 26mg/day
Specialist titration; Dravet/Lennox-Gastaut
Paediatric weight-based calculator
Specialist titration; Dravet/Lennox-Gastaut
Clinical pearls
- Dravet and Lennox-Gastaut syndrome seizures (specialist epilepsy)
- Echocardiogram before treatment, every 6 months on therapy, and 3–6 months after stopping
Contraindications
- Aortic/mitral valve disease
- Pulmonary hypertension
- Concurrent MAOI
- Pregnancy
- Recent (≤14 days) MAOI
Side effects
- Cardiac valvulopathy
- Pulmonary hypertension
- Decreased appetite
- Somnolence
- Diarrhoea
Interactions
- MAOIs (avoid; serotonin syndrome)
- Stiripentol (raises levels — dose adjustment)
- Other serotonergic agents
Monitoring
- Echocardiogram
- Behaviour/mood
- Weight
Reference: BNFc; BNF; NICE TA808; MHRA; SmPC; https://bnf.nice.org.uk/drugs/fenfluramine/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS